CAS No.:359-83-1

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
human	LDLo	oral	18mg/kg (18mg/kg)	LUNGS, THORAX, OR RESPIRATION: BRONCHIECTASIS	Clinical Toxicology. Vol. 10, Pg. 327, 1977.
human	TDLo	intramuscular	571ug/kg (0.571mg/kg)	BEHAVIORAL: EUPHORIA GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"	Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964.
human	TDLo	intravenous	300mg/kg/D (300mg/kg)	BEHAVIORAL: ANALGESIA BEHAVIORAL: WITHDRAWAL	British Medical Journal. Vol. 2, Pg. 21, 1978.
mammal (species unspecified)	LD50	intraperitoneal	140mg/kg (140mg/kg)		United States Patent Document. Vol. #4205173,
man	TDLo	intramuscular	83mg/kg/4Y-I (83mg/kg)	MUSCULOSKELETAL: JOINTS	Archives of Internal Medicine. Vol. 143, Pg. 2203, 1983.
man	TDLo	intravenous	3mg/kg/2D-I (3mg/kg)	BEHAVIORAL: WAKEFULNESS BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: EXCITEMENT	Journal of Pharmacology and Experimental Therapeutics. Vol. 143, Pg. 149, 1964.
mouse	LD50	intramuscular	98mg/kg (98mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
mouse	LD50	intraperitoneal	85mg/kg (85mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ANALGESIA BEHAVIORAL: ATAXIA	Chemical and Pharmaceutical Bulletin. Vol. 24, Pg. 2912, 1976.
mouse	LD50	intravenous	19800ug/kg (19.8mg/kg)		Drugs in Japan Vol. 6, Pg. 777, 1982.
mouse	LD50	oral	305mg/kg (305mg/kg)		Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
mouse	LD50	subcutaneous	140mg/kg (140mg/kg)		Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
rat	LD50	intramuscular	175mg/kg (175mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
rat	LD50	intravenous	21mg/kg (21mg/kg)		"Synthetic Analgesics," Oxford, Pergamon Press, 1966Vol. 2, Pg. 174, 1966.
rat	LD50	oral	1110mg/kg (1110mg/kg)	AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 2145, 1970.
rat	LD50	subcutaneous	165mg/kg (165mg/kg)		Acta Medicia Okayama. Vol. 35, Pg. 179, 1981.
rat	LD50	unreported	280mg/kg (280mg/kg)	BEHAVIORAL: ANALGESIA	Pharmacological Research Communications. Vol. 5, Pg. 175, 1973.
women	TDLo	intramuscular	1400mg/kg/3Y (1400mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: MUSCLE WEAKNESS SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	JAMA, Journal of the American Medical Association. Vol. 231, Pg. 271, 1975.

Consensus Reports：

 

SAFETY PROFILE：

Poison by ingestion, subcutaneous, intramuscular, intraperitoneal, and intravenous routes. Experimental reproductive effects. Human systemic effects by intramuscular and intravenous routes: wakefulness, euphoria, hallucinations or distorted perceptions, tremors, convulsions, excitement, motor activity changes, muscle weakness, analgesia, withdrawal, parasympathomimetic effects, nausea or vomiting, and dermititis. Can cause drug dependency and other central nervous system effects. An analgesic. When heated to decomposition it emits toxic fumes of NO_x. See also ALLYL COMPOUNDS.Safety information of 2-(3,3-Dimethylallyl)cyclazocine (CAS NO.359-83-1):
Hazard Codes  Xn
Risk Statements  
R22:Harmful if swallowed. 
RTECS  PB8750000

Standards and Recommendations：

 

Analytical Methods：